Naproxen sodium and caffeine (BAY2880376) + Naproxen sodium (Aleve) + Caffeine + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Postoperative Dental Pain
Conditions
Postoperative Dental Pain
Trial Timeline
Sep 21, 2022 → Jan 29, 2024
NCT ID
NCT05485805About Naproxen sodium and caffeine (BAY2880376) + Naproxen sodium (Aleve) + Caffeine + Placebo
Naproxen sodium and caffeine (BAY2880376) + Naproxen sodium (Aleve) + Caffeine + Placebo is a phase 3 stage product being developed by Bayer for Postoperative Dental Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT05485805. Target conditions include Postoperative Dental Pain.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05485805 | Phase 3 | Completed |
Competing Products
20 competing products in Postoperative Dental Pain